Ankylosing Spondylitis Study (130 Weeks)

Men and women aged 18 years and older with a diagnosis of moderate to severe Ankylosing Spondylitis (AS), may qualify to participate in this study. Participants will receive an approved medication (secukinumab) via injection or an investigational biosimilar medication (not yet approved).

The length of study participation may last up to 130 weeks. You will be required to attend certain visits at the study site for on-site dosing. For remaining visits, at-home dosing can occur, if preferred. Participants will be reimbursed for study-related expenses.

Call the study centre near you, or register now.

Learn more about
Ankylosing Spondylitis
Register Now!

Participating Locations


  • Sorry no locations are available in this country.


  • Sorry no locations are available in this country.


  • Sorry no locations are available in this country.


  • Sorry no locations are available in this country.

Similar Studies

  • At this time there are no other studies for this condition. Please register to be contacted about upcoming studies for this condition.

Register for
Active Studies!


All information about you will be kept confidential.

If there are no active studies for your condition, we will keep your information and contact you when a new study starts in your area.

By registering you are consenting to the terms and conditions of our privacy policy.

Find the clinic near you:

Why Take Part In a Clinical Study?

Regulatory agencies like Health Canada, Australia's Therapeutic Goods Administration and the FDA require that Clinical Research Trials be conducted in order to develop new treatments, preventions and devices for diseases or conditions. Clinical Research Trials are also referred to as Clinical Studies or Clinical Trials. read more